We identified candidate biomarkers for early ARDS diagnosis and risk assessment.
Eighteen proteins significantly differed in BALFs of mild and severe ARDS patients.
Differential plasma expression of apoA1, SP-A, and DMBT1 was confirmed in ARDS.
DMBT1 may be useful for early ARDS diagnosis and predicting disease severity.